Displaying 1 publication

Abstract:
Sort:
  1. Lau ST, Loo GH, Kong SH, Mustafa N, Kosai NR
    Obes Surg, 2026 Jul;36(7):3777-3784.
    PMID: 42240795 DOI: 10.1007/s11695-026-08781-4
    BACKGROUND: Obesity-associated Type 2 Diabetes Mellitus (T2DM) represents a major and escalating driver of healthcare expenditure in Malaysia. Metabolic bariatric surgery (MBS) offers superior glycaemic outcomes compared with medical therapy, but real-world evidence on direct diabetic medication cost savings in Southeast Asian populations remains limited. This study aimed to evaluate long-term diabetic medication costs and diabetes remission outcomes in patients with obesity and T2DM following MBS compared with medical therapy alone at a single Malaysian academic centre.

    METHODS: This retrospective observational cohort study included 236 patients (bariatric surgery, n = 115; medical therapy, n = 121) with obesity and T2DM managed at Hospital Canselor Tuanku Muhriz (HCTM), Universiti Kebangsaan Malaysia, between 2016 and 2020, with follow-up for up to five years. Direct diabetic medication costs were derived from institutional pharmacy acquisition pricing and compared annually. Diabetes remission was defined according to American Diabetes Association criteria. Multivariable logistic regression was performed to identify independent predictors of remission. Multicollinearity among correlated predictors was assessed using variance inflation factors (VIF).

    RESULTS: Patients in the bariatric cohort had significantly higher baseline BMI (44.8 ± 9.8 vs. 40.0 ± 6.8 kg/m², p 

Related Terms
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links